Sign in Subscribe
Cancer research

Evaluation of siRNA Delivery Platform for Cancer Treatment

Strategic Insights

— 2 min read

Scientists at the University of Marburg, Medical Department, have discovered a novel non-viral delivery platform for therapeutic siRNAs, which shows promise in treating cancer. Researchers have developed pegylated siRNA/cationic liposome (slRNA/PEG-LIC) complexes that exhibit favorable pharmacokinetic properties and biodistribution profiles. These complexes accumulate in subcutaneous prostate carcinoma xenografts, leading to reduced tumor growth by knocking down the anti-apoptotic proto-oncogene bcl-2.

Key Takeaways:

  • The study demonstrates the efficacy of siRNA/PEG-LIC complexes in delivering therapeutic siRNAs to cancer cells, resulting in increased survival rates in mice with ovarian carcinoma.
  • The researchers found that PEGylation of siRNA/cationic liposome complexes improved their pharmacokinetic properties and biodistribution profiles, making them more suitable for systemic siRNA delivery.
  • The combination of siRNA and PEG-LIC complexes effectively knocked down the bcl-2 gene, leading to reduced tumor growth and improved treatment outcomes in mice with prostate carcinoma xenografts.
  • The study suggests that siRNA/PEG-LIC complexes may represent an attractive nanoparticle platform for targeting the proto-oncogene bcl-2 in cancer treatment.
  • The researchers proposed that these complexes could be used as a non-viral delivery platform for therapeutic RNAi, providing a new approach for cancer gene therapy.
  • PEGylation with C-17 or C-18 acyl chains was found to be optimal for improving the pharmacokinetic properties of siRNA/PEG-LIC complexes.
  • The study highlights the potential of PEGylated siRNA/cationic liposome complexes in delivering therapeutic siRNAs to cancer cells, offering a new avenue for cancer treatment.

Statistics:

  • 8843-8851: Page numbers of the study published in Cancer Research (2008)
  • 2009: Year in which the study was published in Future Oncology
  • 5(1):13-17: Issue and page numbers of the study published in Future Oncology (2009)
  • 68: Volume number of the study published in Cancer Research (2008)
  • 2 Albert Place: Address of Future Medicine Ltd., the publisher of the journal Future Oncology
  • N3 1QB: Postcode of Future Medicine Ltd., the publisher of the journal Future Oncology

Sources:

  • Sonoke S, Ueda T, Fujiwara K et al. (2008). Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 68, 8843-8851.
  • Hobel S, et al. (2009). Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. Future Oncology, 2009;5(1):13-17.
  • Cancer Gene Therapy Week editors (2009). Evaluation of siRNA delivery platform for cancer treatment. Cancer Gene Therapy Week, via NewsRx.com.

Read more